| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/12/2002 | US20020127598 Modulator for use in the diagnosis, treatment and prevention of bacterial and viral infection |
| 09/12/2002 | US20020127596 murF2 |
| 09/12/2002 | US20020127558 Genetic polymorphism of MxA protein and use thereof |
| 09/12/2002 | US20020127276 Bio-erodible microbicidal devices for prevention of sexually transmitted diseases; retains antiviral activity at neutral pH and thus does not lose activity in the presence of seminal fluid; vaginal sponge with built-in microbicidal activity |
| 09/12/2002 | US20020127243 Administering dietary supplement comprising soybean, mushroom and mung bean or extracts to ameliorate at least one effect of malignancy or viral infection |
| 09/12/2002 | US20020127242 To reduce the severity or prevent infection by ehrlichial parasites of the species Anaplasma marginale |
| 09/12/2002 | US20020127239 LipL32 polypeptide is useful for inducing an immune response to a pathogenic spirochete in a patient |
| 09/12/2002 | US20020127238 Utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a modified HIV-1 envelope protein or fragment, wherein modified protein having a HIV-1 envelope protein V2 region deletion |
| 09/12/2002 | US20020127235 Identification and molecular characterization of proteins, expressed in the Ixodes ricinus salivary glands |
| 09/12/2002 | US20020127232 Activating alpha 2-macroglobulin by incubation with a nucleophilic compound to form nucleophile-activated alpha 2-macroglobulin, removing excess of nucleophilic compound, incubating activated alpha-2 macroglobulin with biomolecule |
| 09/12/2002 | US20020127215 Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 09/12/2002 | US20020127212 Use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
| 09/12/2002 | US20020127208 Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| 09/12/2002 | US20020127204 Improvements in or relating to protection against intracellular infection |
| 09/12/2002 | US20020127203 Polypeptide having phenylacetyl-coenzyme a ligase activity which has been isolated from culture; for production of penicillin |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | US20020127138 Comprises albumen lysozyme from fowls and glycine for spraying into barns and surroundings |
| 09/12/2002 | DE10110355A1 Bekämpfung von Nebenwirkungen Combat side effects |
| 09/12/2002 | DE10109166A1 Avilamycin-Derivate Avilamycin derivatives |
| 09/12/2002 | DE10108851A1 Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten Use of 5'-substituted nucleosides and / or their prodrugs for the resistance-free therapy of infectious diseases |
| 09/12/2002 | CA2788498A1 Polymorphic and other crystalline forms of cis-ftc |
| 09/12/2002 | CA2440069A1 Taste masked pharmaceutical compositions |
| 09/12/2002 | CA2439990A1 Immunogenic hiv peptides for use as reagents and vaccines |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439836A1 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
| 09/12/2002 | CA2439827A1 Peptide deformylase inhibitors |
| 09/12/2002 | CA2439820A1 Benzophenones as inhibitors of reverse transcriptase |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439666A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| 09/12/2002 | CA2439581A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | CA2439574A1 Catecholate beta-lactam conjugates, method for producing the same and the use thereof |
| 09/12/2002 | CA2439413A1 Virucidal compositions |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439178A1 Template-fixed peptidomimetics with antimicrobial activity |
| 09/12/2002 | CA2438505A1 Altered peptide ligands |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2437592A1 Malic acid addition salts of terbinafine |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2433467A1 Substituted quinolinecarboxamides as antiviral agents |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | CA2431500A1 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| 09/11/2002 | EP1239034A2 Large circular target-specific antisense nucleic acids |
| 09/11/2002 | EP1238674A2 Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF |
| 09/11/2002 | EP1238672A1 Pharmaceutical composition comprising a combined extract of licorice and oak bark |
| 09/11/2002 | EP1238086A1 Method of enhancing immune responses to herpes simplex virus vaccine |
| 09/11/2002 | EP1238084A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238072A2 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 09/11/2002 | EP1238071A2 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses |
| 09/11/2002 | EP1238070A2 Therapeutically useful synthetic oligonucleotides |
| 09/11/2002 | EP1238066A2 Masp-3, a complement-fixing enzyme, and uses for it |
| 09/11/2002 | EP1238016A1 Substituted phthalocyanines and their precursors |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237917A2 Protein c derivatives |
| 09/11/2002 | EP1237914A1 Methods for improving secondary metabolite production in fungi |
| 09/11/2002 | EP1237912A2 Five-helix protein |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237889A1 Antibiotic sultam and sultone derived oxazolidinones |
| 09/11/2002 | EP1237887A1 9-(piperazinylalkyl)carbazoles as bax-modulators |
| 09/11/2002 | EP1237886A1 Heterocyclic derivatives |
| 09/11/2002 | EP1237876A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237866A1 Amycomycin, a process for its production and its use as a pharmaceutical |
| 09/11/2002 | EP1237862A1 Succinate compounds, compositions and methods of use and preparation |
| 09/11/2002 | EP1237845A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/11/2002 | EP1237582A2 Methods for introducing genes into mammalian subjects |
| 09/11/2002 | EP1237578A2 Micro-cluster liquids and methods of making and using them |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237572A2 Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| 09/11/2002 | EP1237567A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 09/11/2002 | EP1237562A2 Dna polymerase inhibitors, mikanolide and dihydromikanolide |
| 09/11/2002 | EP1237558A1 Novel helicobacter pylori-binding substances and use thereof |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |
| 09/11/2002 | EP1237546A2 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 09/11/2002 | EP1237544A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 09/11/2002 | EP1133500B1 Organophosphorous compounds and the use thereof |
| 09/11/2002 | EP1067936B1 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| 09/11/2002 | EP1049480B1 Herbal anti-viral agent |
| 09/11/2002 | EP0813529B1 Arginine analogues having nitric oxide synthase inhibitor activity |
| 09/11/2002 | EP0797445B1 Use of bioassimilable aqueous boron compounds for the control of subviral pathogenic agents |
| 09/11/2002 | EP0763036B1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| 09/11/2002 | EP0668860B1 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses |
| 09/11/2002 | CN1369011A Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| 09/11/2002 | CN1369009A Modified chimeric polyeptides with improved pharmacokinetic properties |
| 09/11/2002 | CN1368970A Substituted 1,4-dihydroindeno [1,2-C] pyrazoles as inhibitors of tyrosine kinase |
| 09/11/2002 | CN1368960A Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 09/11/2002 | CN1368957A Aminobenzophenones as inhibiotors of IL-1 beta and TNF-alpha |
| 09/11/2002 | CN1368953A Aminobenzophenones as inhibitors of IL-1 bata and TNF-alpha |
| 09/11/2002 | CN1368950A Novel aminobenzophenones |
| 09/11/2002 | CN1368891A Moxilfloxacin formulation containing common salt |
| 09/11/2002 | CN1368887A Mycophenolate Mofetil in association with PEG-IFN alpha |